These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 6610103)

  • 61. Effects of serum immunosuppressive factors on antitumor cytotoxicity of interleukin 2-induced lymphocytes.
    Sugiyama Y; Sakata K; Saji S; Takao H; Hamuro J
    J Surg Oncol; 1987 Aug; 35(4):223-9. PubMed ID: 3497306
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Depression of the generation of cell-mediated cytotoxicity after surgery.
    Miyazaki S; Akiyoshi T; Arinaga S; Koba F; Tsuji H
    Jpn J Surg; 1983 May; 13(3):191-5. PubMed ID: 6632392
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Human primary T-cell lines in lectin-free media.
    Fabricius HA; Stahn R
    Immunobiology; 1980 Jan; 156(4-5):364-71. PubMed ID: 6966253
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Natural killer activity and serum immunosuppressive acidic protein levels in esophageal and gastric cancers.
    Oka M; Mitsunaga H; Hazama S; Yoshino S; Suzuki T
    Surg Today; 1993; 23(8):669-74. PubMed ID: 8400669
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Immune function of cancer patients with spleen-deficiency syndrome].
    Yu RC; Guan CF; Zhang JH
    Zhong Xi Yi Jie He Za Zhi; 1990 Sep; 10(9):535-7, 516. PubMed ID: 2268941
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Cytotoxic activity of tumor-infiltrating lymphocytes and macrophages in gastric cancer].
    Shirato M
    Nihon Shokakibyo Gakkai Zasshi; 1985 Jul; 82(7):1665-74. PubMed ID: 4079085
    [No Abstract]   [Full Text] [Related]  

  • 67. [The relationship of natural killer activity with progression of gastric cancer (author's transl)].
    Tanaka Y; Aoike A; Hosokawa T; Yamaguchi N; Akasaka Y
    Nihon Shokakibyo Gakkai Zasshi; 1979 Dec; 76(12):2456. PubMed ID: 529525
    [No Abstract]   [Full Text] [Related]  

  • 68. The possible use of spleen cells for the adoptive immunotherapy of cancer patients.
    Katano M; Yamamoto H; Kubota E; Nakamura M; Matsuo T; Nagumo F; Hisatsugu T; Katsuki T; Tadano J
    Surg Today; 1993; 23(1):13-20. PubMed ID: 8461601
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The regulation of natural killer cell activity by splenic nonspecific suppressor cells and its modification in cancer patients.
    Yanagawa E; Toge T; Sawamura A; Kegoya Y; Baba N; Hattori T
    Jpn J Surg; 1988 Nov; 18(6):660-7. PubMed ID: 2977625
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Activated killer cell activity of spleen cells from patients with gastric carcinoma.
    Akiyoshi T; Koba F; Arinaga S; Tsuji H
    J Clin Lab Immunol; 1987 Aug; 23(4):197-201. PubMed ID: 2959788
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [The effect of sera of breast cancer patients on NK cell activity].
    Konjević G; Spuzić I
    Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
    Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
    Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism.
    Rook AH; Hooks JJ; Quinnan GV; Lane HC; Manischewitz JF; Macher AM; Masur H; Fauci AS; Djeu JY
    J Immunol; 1985 Mar; 134(3):1503-7. PubMed ID: 3918102
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [NK activity, TCGF production and generation of cell-mediated cytotoxicity in spleen cells from gastric cancer patients].
    Akiyoshi T; Koba F; Miyazaki S; Arinaga S; Tsuji H
    Nihon Geka Gakkai Zasshi; 1983 Sep; 84(9):957-60. PubMed ID: 6610103
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.